{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:31:49Z","timestamp":1773779509087,"version":"3.50.1"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T00:00:00Z","timestamp":1754092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370201"],"award-info":[{"award-number":["82370201"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.clim.2025.110575","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:08:28Z","timestamp":1754424508000},"page":"110575","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation"],"prefix":"10.1016","volume":"279","author":[{"given":"Xing-Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Meng","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaroslav","family":"Kaminskiy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Wei","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Qing","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2025.110575_bb0005","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13797","article-title":"Postautologous stem cell transplantation engraftment syndrome: improved treatment and outcomes","volume":"34","author":"Liu","year":"2020","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.clim.2025.110575_bb0010","doi-asserted-by":"crossref","first-page":"e775","DOI":"10.1016\/j.clml.2021.06.004","article-title":"Budesonide prophylaxis reduces the risk of engraftment syndrome after autologous hematopoietic cell transplantation in multiple myeloma","volume":"21","author":"Dhakal","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.clim.2025.110575_bb0015","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1703855","article-title":"Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria","volume":"31","author":"Maiolino","year":"2003","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0020","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/bmt.2014.296","article-title":"Engraftment syndrome: double-edged sword of hematopoietic cell transplants","volume":"50","author":"Spitzer","year":"2015","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2021.101513","article-title":"Evaluation of cytokine profile in the different phases of the autologous hematopoietic stem cell transplantation in patients with multiple myeloma","volume":"70","author":"Callera","year":"2022","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.clim.2025.110575_bb0030","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/bmt.2009.363","article-title":"Engraftment syndrome after auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center","volume":"45","author":"Carreras","year":"2010","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0035","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.bbmt.2013.06.017","article-title":"Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma","volume":"19","author":"Cornell","year":"2013","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0040","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/j.bbmt.2019.05.035","article-title":"Autologous stem cell transplantation for multiple myeloma: growth factor matters","volume":"25","author":"Chen","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0045","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/1078-0432.CCR-13-2442","article-title":"Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation","volume":"20","author":"Wang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2025.110575_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2024.156582","article-title":"Serum cytokine profiles during engraftment syndrome and acute graft-versus-host disease in adult patients after hematopoietic stem cell transplantation","volume":"178","author":"Wu","year":"2024","journal-title":"Cytokine"},{"key":"10.1016\/j.clim.2025.110575_bb0055","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.25378","article-title":"Procalcitonin as a biomarker to differentiate bacterial infections from engraftment syndrome following autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"94","author":"Knoll","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clim.2025.110575_bb0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.bmt.1705138","article-title":"Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg\/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects","volume":"36","author":"Rossi","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.clim.2025.110575_bb0065","first-page":"110 e111","article-title":"Characteristics of engraftment syndrome following autologous stem cell transplantation in light chain amyloidosis with renal involvement","volume":"29","author":"Miao","year":"2023","journal-title":"Transplant. Cell Ther."},{"key":"10.1016\/j.clim.2025.110575_bb0070","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/intimm\/dxp102","article-title":"IL-5- and eosinophil-mediated inflammation: from discovery to therapy","volume":"21","author":"Kouro","year":"2009","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2025.110575_bb0075","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/all.12311","article-title":"CD8(+) T cells producing IL-3 and IL-5 in non-IgE-mediated eosinophilic diseases","volume":"68","author":"Stoeckle","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.clim.2025.110575_bb0080","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.clim.2025.110575_bb0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.4049\/jimmunol.167.1.424","article-title":"Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection","volume":"167","author":"Dobrzanski","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2025.110575_bb0090","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.3324\/haematol.2020.261842","article-title":"Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib\/thalidomide\/dexamethasone in the phase 3 CASSIOPEIA study","volume":"106","author":"Hulin","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2025.110575_bb0095","doi-asserted-by":"crossref","first-page":"610","DOI":"10.3324\/haematol.2022.281610","article-title":"Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients","volume":"108","author":"Lemonakis","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2025.110575_bb0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001500?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661625001500?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T20:38:18Z","timestamp":1762547898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661625001500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"alternative-id":["S1521661625001500"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2025.110575","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interleukin-5 is an adjunctive biomarker for engraftment syndrome in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2025.110575","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110575"}}